Riskpilot← Back to searchSign inGet full accessJENSEN BIOCONSULT ApS
APSActiveCVR 35670491Højdevej 15Research and experimental development on natural sciences and engineering · NACE 7210Est. 20141 employees
Revenue 2024
DKK -4K
+270% vs 2023
EBITDA margin
100.0%
-270% vs 2023
Equity ratio
-19.4%
Financial strength
Net profit 2024
DKK -25K
-23% vs 2023
| Revenue | DKK -4K | +270% |
| EBITDA | DKK -4K | -270% |
| Net profit | DKK -25K | -23% |
| Total assets | DKK 237K | -2% |
| Equity | DKK -46K | -116% |
| Employees | 1 | — |
Legal name
JENSEN BIOCONSULT ApS
CVR number
35670491
Legal form
Anpartsselskab
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
1. februar 2014
Share capital
DKK 40.000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af direktøren.
Company purpose
Selskabets formål er rådgivning og bistand indenfor bioteknologi samt investering i biotekvirksomheder, rådgivning og udvikling, EU bevillinger mm. samt efter direktionens skøn dermed beslægtet virksomhed.
Address
Højdevej 15
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 83 | 45 | -7 | -4 | 5 | 6 | -7 | -6 | -5 | -1 | -4 |
| Staff expenses | -44 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBITDA | 19 | 38 | -7 | -4 | 5 | 6 | -7 | -6 | -5 | -1 | -4 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBIT | 19 | 38 | -7 | -4 | 5 | 6 | -7 | -6 | -5 | -1 | -4 |
| Net financials | -5 | -1 | -1 | 0 | 0 | -0 | -8 | -9 | -10 | -19 | -21 |
| Profit before tax | 15 | 38 | -8 | -4 | 5 | 5 | -15 | -14 | -15 | -20 | -25 |
| Tax | 5 | 9 | -1 | 2 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| Net profit | 10 | 29 | -6 | -6 | 5 | 5 | -15 | -14 | -15 | -20 | -25 |
| Item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 41 | 55 | 43 | 37 | 41 | 147 | 146 | 135 | 234 | 241 | 237 |
| Equity | 10 | 46 | 39 | 34 | 38 | 43 | 29 | 14 | -1 | -21 | -46 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 31 | 9 | 4 | 4 | 3 | 103 | 117 | 120 | 235 | 262 | 283 |
| Total debt | 31 | 9 | 4 | 4 | 3 | 103 | 117 | 120 | 235 | 262 | 283 |
EBITDA margin
-405000.0%
This company
15.8%
Market median
-2563391% vs market
20142024
Equity ratio
-19.4%
This company
38.2%
Market median
-151% vs market
20142024
Return on equity
-2469000.0%
This company
18.4%
Market median
-13418578% vs market
20142024
Net profit margin
-2469000.0%
This company
8.1%
Market median
-30481581% vs market
20142024
Asset turnover
-0.02×
This company
1.12×
Market median
-102% vs market
20142024
Debt / equity
6.16×
This company
0.62×
Market median
-894% vs market
20142024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via CVR / Virk · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via CVR / Virk · Period 2014-02-01 – 2014-12-31
No data on file.
No data on file.
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 100.0% | 100.0% | 2014 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
JENSEN BIOCONSULT ApS 
MonTa Biosciences ApSBoard members of JENSEN BIOCONSULT ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|